Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia

Journal of Pathology

Volumn 178, Issue 2, 1996, Pages 133-139

  Furihata, Mutsuo ^a   Sonobe, Hiroshi ^a   Ohtsuki, Yuji ^a   Yamashita, Motoyuki ^a   Morioka, Masaaki ^a   Yamamoto, Akihiro ^b   Terao, Naotami ^b   Kuwahara, Morimasa ^c   Fujisaki, Nobuta ^c  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b Kochi Takasu Hospital   (Japan)

^c Fujisaki Hospital   (Japan)

Author keywords

bcl 2; Direct sequence; Dysplasia; Immunohistochemistry; p53; Renal pelvis; Southern blot analysis; Transitional cell carcinoma; Ureter

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ARTICLE; CONTROLLED STUDY; EPITHELIUM DYSPLASIA; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY PELVIS CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SOUTHERN BLOTTING; TRANSITIONAL CELL CARCINOMA; URETER CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BLOTTING, SOUTHERN; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENES, P53; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; URETERAL NEOPLASMS;

EID: 0030065136     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199602)178:2<133::AID-PATH455>3.0.CO;2-F     Document Type: Article

References (36)

1. Levin AJ, Momad J, Finlay CA. The p53 tumor suppressor gene. Nature 1991: 351:453-456.
2. Hollstein M, Sidrensky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
3. Weinberg RA. Tumor suppressor genes. Science 1991, 254: 1138-1146.
4. Furihata M, Inoue K, Ohtsuki Y, Hashimoto H, Terao N, Fujita Y. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder. Cancer Res 1993; 53: 4823-4827.
5. Olumi AF, Tsai YC, Nichols PW, et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 1990, 50: 7081-7083.
6. Sidransky D, Eschenbach AV, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples Science 1991, 252: 706-709.
7. Fujimoto K, Yamada Y, Okajima E, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992, 52: 1393-1398.
8. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85: 53-59.
9. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value Int J Cancer 1993; 53; 365-370.
10. Esrig D, Spruck CH III, Nichols PW, et al p53 nuclear protein accumulation correlates with mutations m the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389-B97.
11. Spruck CH III, Rideout WM III, Olumi AF, et al. Distinct pattern of p53 mutations in bladder cancer: relationship to tobacco usage. Cancer Res 1993; 53: 1162-1166.
12. Habuchi T, Takahashi R, Yamada H, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 1993; 53: 3795-3799.
13. Habuchi T, Ogawa O, Kakehi Y, et al. Accumulated allelic losses in the development of invasive urothelial cancer. Int J Cancer 1993, 53: 579-584.
14. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 54: 784-788.
15. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sa USA 1986; 83: 5214-5218.
16. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death Proc Natl Acad Sci USA 1991; 88: 6961-6965.
17. Pezzella F, Ralfkiaer E, Gatter KC, Mason DY The 14;18 translocation in European cases of follicular lymphoma. comparison of Southern blotting and the polymerase chain reaction. Br J Haematol 1990, 76: 58-64.
18. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993, 329: 690-694.
19. McDonnell TJ, Troncoso P, Brisbay SM, et al Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-6944.
20. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994; 424: 47-51.
21. Charlotte F, L'Herminé A, Martin N, et al. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am J Pathol 1994; 144: 460-465.
22. Yonish-Rouach E, Rensmitzki D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 1991; 352: 345-347.
23. Vaux DL, Cory S, Adams JM. bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440-442.
24. Lotem J, Sachs L Regulation by bcl~2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 1993; 4: 41-47.
25. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogens 1993; 8: 3427-3431.
26. Sander CA, Yano T, Clarck HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 1994-2004.
27. Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo Oncogene 1994; 9: 1799-1805.
28. Halder S, Negrini M, Monne M, Sabbioni S, Croce CM. Down regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994; 54: 2095-2097.
29. Japanese Urological Association and the Society of Pathology. General Rules for Clinical and Pathological Studies on Renal Pelvic and Ureteral Cancer. 1st edn. Tokyo Kanehara, 1990; 45-62.
30. Shi SR, Key ME, Kalra K. Antigen retrieval in formalin-fixed, paraffinembedded tissues; an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections J Histochem Cytochem 1991; 39: 741-748.
31. Shin RW, Iwaki T, Kitamoto T, Tateishi J Hydrated autoclave pretreatment enhances TAU immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues. Lab Invest 1991; 64: 693-702.
32. Kogan SC, Doherty M, Gitschier J. An improved method for prenatal diagnosis of genetic disease by analysis of amplified DNA sequences. N Engl J Med 1987; 317: 985-990.
33. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oricogene in primary lung cancer. Lancet 1990; i: 675-679.
34. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
35. Weinert T, Lydall D. Cell cycle check points, genetic instability and cancer. Semi Cancer Biol 1993, 4: 129-140.
36. Nun̄ez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated bcl-2 gene expression selectively prolongs survival of growth facto r-deprived hemopoietic cell lines. J Immunol 1990, 144: 3602-3610.